Fortrea Holdings, Inc. (FTRE)

20.46 -0.37 (-1.78%) USD  |  NASDAQ  |  Nov 05, 16:00
20.48 +0.02 (+0.10%) After-Hours: 20:00
More

Fortrea Holdings SG&A Expense (TTM) : 409.40M for Sept. 30, 2026

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2022. Start Trial.
Date Value
September 30, 2026 409.40M
June 30, 2026 412.40M
March 31, 2026 435.10M
December 31, 2025 456.40M
September 30, 2025 501.50M
June 30, 2025 531.00M
March 31, 2025 562.40M
December 31, 2024 560.70M
September 30, 2024 511.50M
June 30, 2024 482.00M
Date Value
March 31, 2024 423.60M
December 31, 2023 420.30M
September 30, 2023 321.40M
June 30, 2023 285.30M
March 31, 2023 258.70M
December 31, 2022 216.90M
September 30, 2022 216.90M
June 30, 2022 146.20M
March 31, 2022 75.00M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Charles River Laboratories International, Inc. 584.46M
IQVIA Holdings, Inc. 2.113B
Medpace Holdings, Inc. 192.70M
Champions Oncology, Inc. 21.81M
Avantor, Inc. 1.604B